|
Academic/Biomedical Research
News & Jobs
|
|
|
|
|
|
|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions

News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia


Company Profiles

Research Store

Research Events
Post an Event

Real Estate
Business Opportunities
|
|
|
|
|
PLoS By Category | Recent
PLoS Articles
|
|
Biochemistry - Diabetes and Endocrinology - Hematology - Neurological Disorders - Neuroscience - Physiology
|
The Preventive and Therapeutic Effects of Intravenous Human Adipose-Derived Stem Cells in Alzheimer’s Disease Mice
Published:
Wednesday, September 26, 2012
Author:
Saeromi Kim et al.
by Saeromi Kim, Keun-A Chang, Jeong a. Kim, Hyeong-Geun Park, Jeong Chan Ra, Hye-Sun Kim, Yoo-Hun Suh
Alzheimer’s disease (AD) is characterized by the accumulation of amyloid plaques and neurofibrillary tangles accompanied by cognitive dysfunction. The aim of the present study was to elucidate preventive and therapeutic potential of stem cells for AD. Among stem cells, autologous human adipose-derived stem cells (hASCs) elicit no immune rejection responses, tumorigenesis, or ethical problems. We found that intravenously transplanted hASCs passed through the BBB and migrated into the brain. The learning, memory and pathology in an AD mouse model (Tg2576) mice greatly improved for at least 4 months after intravenous injection of hASC. The number of amyloid plaques and Aß levels decreased significantly in the brains of hASC-injected Tg mice compared to those of Tg-sham mice. Here, we first report that intravenously or intracerebrally transplanted hASCs significantly rescues memory deficit and neuropathology, in the brains of Tg mice by up-regulating IL-10 and VEGF and be a possible use for the prevention and treatment of AD.
More...
|
|
|
 |
 |
|
|
|
|
|
|
|
|